tiprankstipranks
Trending News
More News >

Coya Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $20 price target Coya is developing a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, the analyst tells investors in a research note. The firm sees an unmet need in amyotrophic lateral sclerosis.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1